HAT1 promotes PC and castration-resistant prostate cancer (CRPC) progression by upregulating AR (including AR-V7) via a BRD4-mediated pathway; knockdown re-sensitizes CRPC cells to ENZ. Here, HAT1 is linked to pachyonychia congenita.